What this release says
The FDA approved a labeling change (SUPPL-15) to Novartis’s NDA 019500 for LAMPRENE, with the approval dated 11/03/2026. The filing does not describe what the labeling change covers, and the label itself is not available on the FDA site. Both LAMPRENE strengths are listed as discontinued, so this approval has limited direct bearing on current sales for a shareholder.
Key figures
Original approval date12/15/1986
Latest supplement approval11/03/2026
Active ingredient strengths50MG and 100MG
Negative for shareholdersBoth LAMPRENE strengths are listed as discontinued.
Written by Quantisnow AI from this release. Not financial advice.
This insight was delivered by Quantisnow – Wall Street’s wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NVS (Novartis AG) and more on Quantisnow.